BIOSECURE Act Excluded from Defense Bill, Easing Pressure on Chinese Biotech
TL;DR Summary
The BIOSECURE Act, which aims to restrict U.S. pharmaceutical companies from using Chinese contract manufacturers like WuXi AppTec and WuXi Biologics, was excluded from a crucial defense budget bill. This legislation, supported by both parties, seeks to reduce reliance on China in the drug supply chain and maintain U.S. dominance in biotechnology. However, the exclusion from the defense bill represents a significant setback for the act.
Topics:business#biosecure-act#bipartisan-support#chinese-manufacturers#defense-budget#politics#us-drugmakers
- BIOSECURE Act, aimed at Chinese drug manufacturers, is dealt a major blow STAT
- Biosecure Act Out of Key Defense Bill in Win for Chinese Biotech Bloomberg
- Reprieve for Chinese biotechs as BIOSECURE Act left out of key bill Yahoo! Voices
- Biosecure compromise in the works, fate uncertain as deadline nears BioCentury
- Biosecure Act left out of defense authorization bill Axios
Reading Insights
Total Reads
0
Unique Readers
2
Time Saved
1 min
vs 1 min read
Condensed
66%
194 → 66 words
Want the full story? Read the original article
Read on STAT